EUCTR2009-015318-23-DE进行中（未招募）1 期
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use PHI in accordance with national and local subject privacy regulations.
- •2. Must be a subject from Study 205MS202 who completed at least 52 weeks and must have been compliant with the 205MS202 protocol in the opinion of the Investigator.
- •3. Women of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 4 months after their last dose of study treatment.
- •Autoinjector PK Substudy Inclusion Criteria:
- •To be eligible for enrollment into the autoinjector substudy, subjects must also meet the following eligibility criteria at the time of randomization into the substudy:
- •4. Ability to understand the purpose and risks of the substudy and provide signed and dated informed consent.
- •5. Must have received at least 6 consecutive monthly doses of 150 mg DAC HYP in Study 205MS203. Note: Subjects are allowed to receive both vialed material and PFS material prior to randomization.
- •6. Must have a Body Mass Index within the range 18 to 32 kg/m2, inclusive.
- •Inclusion criteria for the 2013-2014 Influenza Vaccine Substudy:
- •1. Subjects must provide specific informed consent for the 2013-2014 Influenza Vaccine Substudy
- •2. Subjects must have completed at least 3 months of uninterrupted therapy with DAC HYP prior to entering the 2013-2014 Influenza Vaccine Substudy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 450
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects with any significant change in their medical status from the previous study that would preclude administration of DAC HYP, including laboratory tests or a current clinically- significant condition that, in the opinion of the Investigator, would have excluded the subject's participation in the 205MS201 or 205MS202 studies. The Investigator must re review the subject's medical fitness for participation and must consider any diseases that would preclude treatment.
- •2. Any subject who has permanently discontinued study treatment in Study 205MS202 due to an AE.
- •3. Current enrollment in any investigational drug study other than
- •4. Ongoing treatment with any approved or experimental diseasemodifying treatment for MS.
- •5.For subjects currently taking valproic acid, carbamazepine, lamotrigine, or phenytoin: Subjects treated with any of these agents for fewer than 6 months prior to study entry are excluded from study participation unless they discontinue the agent(s) prior to study entry.*
- •- Subjects treated with 2 or more of these agents for more than 6
- •months prior to study entry are excluded from study participation unless they reduce to =1 agent prior to study entry.*
- •- Subjects who have had dose escalations of one of these agents within the 6 months prior to study entry are excluded from study participation unless they revert to a previous dose that had been used for at least 6 months prior to study entry or unless they discontinue the agent prior to study entry.*
- •*Subjects may use an alternative medication allowed by the protocol as needed.
- •Note: Subjects who have been taking 1 of these medications at a stable dose for at least 6 consecutive months prior to study entry may continue to receive the medication without alteration and are eligible for study participation.
- •6. Subjects who are currently receiving treatment with isoniazid,
- •propylthiouracil, or nimesulide at the time of study entry and are not able to discontinue the agent or change to an alternative medication allowed by the protocol prior to initiation of study treatment in this study.
- •7. Unwillingness or inability to comply with the requirements of the
- •protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol.
- •Autoinjector PK Substudy Exclusion Criteria:
- •Subjects will be excluded from enrollment into the autoinjector substudy if any of the following exclusion criteria exist at the time of randomization into the substudy:
- •8. Any clinically significant adverse event, in the opinion of the Investigator, that is ongoing at the time of randomization.
- •9. ALT or AST greater than the upper limit of normal (>ULN). Testing must have been performed within 30 days prior to randomization.
- •10. Unwillingness or inability to comply with the requirements of the substudy.
- •Exclusion Criteria for the 2013-2014 Influenza Vaccine Substudy:
- •1. Subject has had a severe allergic reaction (e.g., anaphylaxis) to eggs, egg proteins (a vaccine component), or any other component of the trivalent seasonal influenza vaccine.
- •2. Subject has had a serious reaction to previous influenza vaccination.
- •3. Subject has a known latex allergy.
- •4. Subject was previously vaccinated for the 2013-2014 influenza season strain.
- •5. Subject had a respiratory illness in the 2 weeks preceding the planned vaccination with the 2013-2014 trivalent seasonal influenza vaccine.
- •6. Subject
研究者
相似试验
招募中
1 期
ong-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic MigraineEpisodic MigraineMedDRA version: 22.0Level: LLTClassification code: 10082019Term: Episodic migraine Class: 10029205MedDRA version: 20.0Level: PTClassification code: 10027607Term: Migraine with aura Class: 100000004852MedDRA version: 20.0Level: PTClassification code: 10052787Term: Migraine without aura Class: 100000004852CTIS2022-501099-24-00Abbvie Deutschland GmbH & Co. KG246
进行中（未招募）
1 期
A study designed to determine safety and efficacy of Daclizumab HighYield Process (DAC HYP) in patients with Multiple Sclerosis Who HaveCompleted Treatment in a previous study, 205MS202 (SELECTION)Relapsing-remitting Multiple SclerosisMedDRA version: 19.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-015318-23-CZBiogen Idec Ltd.450
进行中（未招募）
1 期
A study designed to determine safety and efficacy of Daclizumab HighYield Process (DAC HYP) in patients with Multiple Sclerosis Who HaveCompleted Treatment in a previous study, 205MS202 (SELECTION)EUCTR2009-015318-23-HUBiogen Idec Ltd.450
已完成
2 期
ong-term Extension Study to Evaluate the Safety and Efficacy of Daclizumab High Yield ProcessCTRI/2012/05/002705Biogen Idec450
进行中（未招募）
1 期
A study designed to determine safety and efficacy of Daclizumab High Yield Process (DAC HYP) in patients with Multiple Sclerosis Who Have Completed Treatment in a previous study, 205MS202 (SELECTION)Relapsing-remitting Multiple SclerosisMedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2009-015318-23-GBBiogen410